Patents by Inventor Verena Aumiller

Verena Aumiller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids for inhibiting expression of C3 in a cell
    Patent number: 11753642
    Abstract: The invention relates to nucleic acid products that interfere with complement component C3 gene expression or inhibit its expression. The nucleic acids are preferably for use as treatment, prevention or reduction of risk of suffering from complement component C3 associated diseases, disorders or syndromes, particularly C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), Lupus nephritis, IgA nephropathy (IgA N), Cold Agglutinin Disease (CAD), Myasthenia gravis (MG), and Primary Membranous Nephropathy.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: September 12, 2023
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Verena Aumiller, Lucas Bethge, Judith Hauptmann, Marie Wikström Lindholm, Adrien Weingärtner
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL
    Publication number: 20230024926
    Abstract: The invention relates to nucleic acid products that interfere with complement component C3 gene expression or inhibit its expression. The nucleic acids are preferably for use as treatment, prevention or reduction of risk of suffering from complement component C3 associated diseases, disorders or syndromes, particularly C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), Lupus nephritis, IgA nephropathy (IgA N), Cold Agglutinin Disease (CAD), Myasthenia gravis (MG), and Primary Membranous Nephropathy.
    Type: Application
    Filed: May 26, 2022
    Publication date: January 26, 2023
    Inventors: Verena Aumiller, Lucas Bethge, Judith Hauptmann, Marie Wikström Lindholm, Adrien Weingärtner
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL
    Publication number: 20220195436
    Abstract: The invention relates to nucleic acid products that interfere with complement component C3 gene expression or inhibit its expression. The nucleic acids are preferably for use as treatment, prevention or reduction of risk of suffering from complement component C3 associated diseases, disorders or syndromes, particularly C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), Lupus nephritis, IgA nephropathy (IgA N), Cold Agglutinin Disease (CAD), Myasthenia gravis (MG), and Primary Membranous Nephropathy.
    Type: Application
    Filed: August 26, 2020
    Publication date: June 23, 2022
    Inventors: Verena Aumiller, Lucas Bethge, Judith Hauptmann, Marie Wikström Lindholm, Adrien Weingärtner
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL
    Publication number: 20220017899
    Abstract: The invention relates to nucleic acid products that interfere with complement component C3 gene expression or inhibit its expression. The nucleic acids are preferably for use as treatment, prevention or reduction of risk of suffering from complement component C3 associated diseases, disorders or syndromes, particularly C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), Lupus nephritis, IgA nephropathy (IgA N), Cold Agglutinin Disease (CAD), Myasthenia gravis (MG), and Primary Membranous Nephropathy.
    Type: Application
    Filed: November 22, 2019
    Publication date: January 20, 2022
    Inventors: Verena Aumiller, Sibylle Dames, Steffen Schubert, Judith Hauptmann, Christian Frauendorf, Marie Wikstrom Lindholm, Adrien Weingartner, Lucas Bethge